[Agranulocytosis--a complication of the chemotherapy of echinococcosis with mebendazole].
Only two of the 75 patients with echinococcosis, treated with mebendazole in a dose of 50 mg/kg b. m. for 30 days (single course) and administered from 1 to 13 courses with intervals of 1 to 3 months, developed agranulocytosis eventuating in death in one female patient. Analysis of blood levels of mebendazole and its metabolites permits a hypothesis that high concentrations thereof may have a toxic effect on the bone marrow, inducing its hypoplasia, in subjects sensitive to these substances.
Shcherbakov
A M
AM
Kozlova
T L
TL
Bebris
N K
NK
D000208:Acute Disease; D000328:Adult; D000380:Agranulocytosis / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D004444:Echinococcosis, Hepatic / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D004445:Echinococcosis, Pulmonary / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008463:Mebendazole / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D013997:Time Factors
D008463:Mebendazole
Agranulotsitoz--oslozhnenie khimioterapii ékhinokokkozov mebendazolom.